AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies February 19, 2025
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer February 11, 2025
Immuneering’s Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab) Announced February 11, 2025
Auron Therapeutics Announces FDA Clearance to Initiate Clinical Development of AUTX-703 and Completion of Series B Financing February 11, 2025
Invenra and Orion Announce Discovery Service and Commercial License Agreement to Develop Innovative Bispecific Antibody Cancer Therapeutics February 11, 2025
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics February 11, 2025
Henlius and Dr. Reddy’s Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. February 11, 2025
Nuvation Bio Announces EAP in the US for Taletrectinib in Advanced ROS1-positive NSCLC February 5, 2025
Imvax Announces Completion of $29 Million Financing and Confirms Timing for Topline Results of Ph 2b Trial of IGV-001 in Newly Diagnosed GBM February 5, 2025
Telix Completes Acquisition of Next-Gen Therapeutic Assets and Innovative Biologics Technology Platform February 4, 2025
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Ph 3 Trial of ANKTIVA and PD-1 Checkpoint Inhibitor Combination in NSCLC February 4, 2025
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals February 4, 2025
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development February 4, 2025
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology January 28, 2025
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology January 21, 2025
Simnova and Orna Expand Strategic Partnership to Include BCMA-Targeted RNA Therapeutics January 21, 2025
ArsenalBio and BMS Achieve Milestone for AB-4000 Series to Advance Next-Gen T Cell Therapies for Solid Tumors January 21, 2025
A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Precision Cell Therapies Using Proprietary Tmod Technology Platform January 21, 2025
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma January 21, 2025
